%0 Journal Article
%A Yoon, Charles H
%A Ross, Merrick I
%A Gastman, Brian R
%A Luke, Jason J
%A Ascierto, Paolo A
%A Long, Georgina V
%A Rutkowski, Piotr
%A Khattak, Muhammad
%A Del Vecchio, Michele
%A de la Cruz Merino, Luis
%A Mackiewicz, Jacek
%A Chiarion-Sileni, Vanna
%A Schadendorf, Dirk
%A Carlino, Matteo S
%A Zhao, Yujie
%A Fukunaga-Kalabis, Mizuho
%A Krepler, Clemens
%A Eggermont, Alexander M M
%A Gershenwald, Jeffrey E
%A Sondak, Vernon K
%T Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.
%J Annals of surgical oncology
%V 32
%N 4
%@ 1068-9265
%C Berlin [u.a.]
%I Springer
%M DKFZ-2025-00268
%P 2756-2764
%D 2025
%Z 2025 Apr;32(4):2756-2764
%X Previous results from the KEYNOTE-716 trial demonstrated significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) with adjuvant pembrolizumab versus placebo in patients with resected stage IIB or IIC melanoma. We present a post hoc analysis of efficacy according to primary tumor location.KEYNOTE-716 (NCT03553836) is a randomized, multicenter, double-blind, phase III study. Patients aged ≥ 12 years with newly diagnosed, resected stage IIB or IIC melanoma (sentinel node-negative) were randomly assigned (1:1) to pembrolizumab 200 mg every 3 weeks (2 mg/kg up to 200 mg for pediatric patients) or placebo. This post hoc analysis evaluated RFS and DMFS by primary tumor location of the head/neck, trunk, or extremities.Overall, 976 patients were assigned to pembrolizumab (n = 487) or placebo (n = 489). Median follow-up was 39.4 months (range 26.0-51.4). The hazard ratios HRs (95
%K Adjuvant (Other)
%K Adjuvant therapy (Other)
%K Immune checkpoint inhibitors (Other)
%K Melanoma (Other)
%K Pembrolizumab (Other)
%K Skin neoplasms (Other)
%K Surgery (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39893343
%R 10.1245/s10434-024-16642-6
%U https://inrepo02.dkfz.de/record/298412